RxDoctor Payments Data

Staci Thompson

Family · Kokomo, INNPI 1417400755

Payments from drug & device makers

$1,576in general payments, 2019–2025

Across 90 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$478
  • Abbott$324
  • Lilly USA, LLC$315
  • Novo Nordisk$93
  • Exact Sciences$89
  • GSK$62
  • plus $216 from 9 others

What the payments were for

  • Food & beverage$1,53797%
  • Education$393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,576 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$30,669
Medicare patients
189
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin79$93,490
OzempicSemaglutide49$61,391
EliquisApixaban40$43,273
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$38,041
Wellbutrin XlBupropion Hcl12$29,963
TrulicityDulaglutide14$27,231
MounjaroTirzepatide13$26,268
ProliaDenosumab13$22,480
XareltoRivaroxaban11$17,534
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$16,533
Breo ElliptaFluticasone/Vilanterol20$11,877
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$7,781
Albuterol Sulfate HfaAlbuterol Sulfate149$6,706
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$6,179
SymbicortBudesonide/Formoterol Fumarate18$4,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$24$93,49079 claims
Novo NordiskOzempic$93$61,39149 claims
Lilly USA, LLCTrulicity, Mounjaro$315$53,49927 claims
GSKTrelegy Ellipta, Breo Ellipta$62$49,91850 claims
AmgenProlia$43$22,48013 claims
AstraZenecaBreztri Aerosphere, Symbicort$11$21,22236 claims
AbbVieSynthroid$478$1,30113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →